Key result
Serum TMAO levels were significantly and independently correlated with central arterial stiffness among patients undergoing peritoneal dialysis (AUC 0.737).
Why the study?
TMAO participates in atherogenesis and vascular stiffening linked to cardiovascular complications in peritoneal dialysis patients, but its correlation with central arterial stiffness measured by cfPWV needed assessment.
Is serum TMAO concentration associated with arterial stiffness in patients undergoing chronic peritoneal dialysis?
Cross-Sectional (n=160)
Is serum TMAO concentration associated with arterial stiffness in patients undergoing chronic peritoneal dialysis?
Effect estimate: AUC 0.737
Higher serum TMAO levels are independently associated with increased central arterial stiffness in patients on chronic peritoneal dialysis.
TMAO may signal vascular risk in peritoneal dialysis; hypothesis-generating for causality and interventions, should not change practice.
-oxide (TMAO), a gut microbiome-derived metabolite, participates in the atherogenesis and vascular stiffening that is closely linked with cardiovascular (CV) complications and related deaths in individuals with kidney failure undergoing peritoneal dialysis (PD) therapy. In these patients, arterial stiffness (AS) is also an indicator of adverse CV outcomes. This study assessed the correlation between serum TMAO concentration quantified with high-performance liquid chromatography and mass spectrometry and central AS measured by carotid-femoral pulse wave velocity (cfPWV) in patients with chronic PD. Of the 160 participants included, 23.8% had a cfPWV of ≥10 m/s, which fulfilled the AS criteria. Multivariable logistic regression analysis revealed that TMAO, age, and waist circumference were positively associated with AS. Multivariable stepwise linear regression showed that underlying diabetes, advanced age, waist circumference, systolic blood pressure, and logarithmic-transformed TMAO were independently correlated with cfPWV. The area under the receiver operating characteristic curve for TMAO in differentiating AS from non-AS was 0.737. In conclusion, serum TMAO level was significantly independently correlated with central AS among participants undergoing PD for end-stage kidney failure.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2024) conducted a cross-sectional in End-stage kidney failure undergoing chronic peritoneal dialysis (n=160). Serum Trimethylamine N-Oxide (TMAO) was evaluated on Central arterial stiffness (AS) measured by carotid-femoral pulse wave velocity (cfPWV) (AUC 0.737). Serum TMAO levels were significantly and independently correlated with central arterial stiffness among patients undergoing peritoneal dialysis (AUC 0.737).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: